346 filings
Page 3 of 18
8-K
g2i4ab i3mtqesx
22 Feb 22
Other Events
8:00am
8-K
st7niwwuv
17 Feb 22
PolarityTE Announces Allowance of Fourth U.S. Patent
8:00am
8-K
bhz gm4pon9
11 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:00am
8-K
24pnmz
18 Jan 22
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to
8:00am
8-K
nh66w 6862a2n4yzybka
23 Dec 21
Departure of Directors or Certain Officers
4:30pm
8-K
ruv7jr8v
20 Dec 21
PolarityTE Announces Submission of Complete Response to FDA’s Clinical Hold Correspondence for SkinTE® Investigational New Drug Application
8:00am
8-K
jtp1sz1l s4h
17 Dec 21
Entry into a Material Definitive Agreement
5:00pm
8-K
dfw 4r3hpr2
10 Nov 21
PolarityTE Reports Third Quarter Financial Results and Provides Business Update
7:00am
8-K
imig 7e3wn
7 Oct 21
PolarityTE Provides Update on Investigational New Drug Application
8:00am
8-K
kpsn4 gzaek39veqjg
1 Oct 21
Amendments to Articles of Incorporation or Bylaws
4:46pm
8-K
ke0fuxjy99 kup2k
9 Sep 21
Regulation FD Disclosure
8:01am
8-K
zjm7z c7d58ogp
2 Sep 21
PolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg
8:00am
8-K
zxgv6kwg4ww
27 Aug 21
Departure of Directors or Certain Officers
12:00am
8-K
4ykysa3nr7
24 Aug 21
Departure of Directors or Certain Officers
8:00am
8-K
gvries880h s85bn9roy
16 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
u5ashalob25hsdgf5i
12 Aug 21
PolarityTE Reports Second Quarter Financial Results and Provides Business Update
4:00pm
8-K
iaacx75afi6erk qmho
28 Jul 21
Regulation FD Disclosure
8:00am
8-K
lauonnjoshx6zjt
26 Jul 21
Other Events
8:00am
8-K
wposllnnn
12 Jul 21
PolarityTE Receives Notice of Allowance for Chinese Patent
8:00am
8-K
8rxg31ttn
17 Jun 21
Termination of a Material Definitive Agreement
4:45pm